Ligand Pharmaceuticals Recognized by Cure for Lymphoma Foundation for Contributions to Lymphoma Education, Research and Treatment.Business Editors and Health/Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--Oct. 30, 2001 Company Has Introduced Three Innovative Lymphoma Treatments in Last Three Years Ligand ligand (lĭg`ənd), charged or uncharged molecule with one or more unshared pairs of electrons that can attach to a central metallic atom or ion to form an aggregate known as a complex ion (see chemical bond). Pharmaceuticals Incorporated (Nasdaq: LGND LGND Luminance Ground ) has received the Third Annual "Trailblazer Award" from the Cure For Lymphoma Foundation for its contributions to lymphoma education, research and treatment. The award was presented at the Seventh Annual "Cabaret for the Cure" fund-raiser gala held last night in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . "It is with tremendous pride and gratitude that we pay tribute to Ligand Pharmaceuticals for its commitment to help ease the burden of lymphoma as well as the company's generous contributions to lymphoma causes," said Cure For Lymphoma Foundation president and lymphoma survivor, Jerry Freundlich. The Trailblazer Award was established in 1997 and recognizes pharmaceutical companies for their efforts in improving the quality of life for lymphoma patients. Ligand was recognized for its support of lymphoma research and education and for bringing three innovative lymphoma treatments -- ONTAK(R) (denileukin diftitox denileukin diftitox /den·i·leu·kin dif·ti·tox/ (den?i-loo´kin dif´ti-toks) a genetically engineered construct combining amino acid sequences for specific diphtheria toxin fragments linked to sequences for interleukin-2 (IL-2); used as an ) and Targretin(R) (bexarotene) capsules and gel -- to market in the last three years. Previous winners include Ortho Biotech Inc., Genentech, and IDEC IDEC Instituto Brasileiro de Defesa do Consumidor (Portugese: Brazilian Consumer Protection Agency) IDEC Information Design & End-User Computing IDEC Interior Design Educators Council, Inc. Pharmaceuticals Corporation. "This award exemplifies our commitment to those living with lymphoma," said David Robinson David Robinson or Dave Robinson is a name shared by the following individuals:
This year's "Cabaret for the Cure" is the seventh and final gala for the Cure For Lymphoma Foundation, which merged in October with the Lymphoma Research Foundation of America. These two groups have combined their resources to create the Lymphoma Research Foundation (LRF LRF luteinizing hormone releasing factor. ), the only national organization devoted exclusively to conducting lymphoma research, committed to finding cures for lymphoma, and dedicated to individuals and families touched by these cancers. Ligand has played an instrumental role in helping these two organizations come together. The LRF will deliver a full spectrum of outstanding professional and public programs to serve the informational, educational, emotional and psychological needs of lymphoma patients and their families. For patient or professional information from the LRF, call 800-500-9976, or call 800-235-6848 for research, advocacy or fund-raising. More information also can be found at www.cfl.org and www.lymphoma.org. Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription Gene transcription The process by which genetic information is copied from DNA to RNA, resulting in a specific protein formation. Mentioned in: Gene Therapy technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs). Information contained in this press release that is not historical may be forward-looking. Forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. and actual results could differ materially from those described as a result of factors including, but not limited to, the following: there can be no assurance that Ligand will be successful in its development and commercialization of innovative treatments. Additional information concerning these and other factors affecting Ligand's business can be found in press releases and in Ligand's public periodic filings with the Securities and Exchange Commission, which are available via Ligand's web site at www.ligand.com. Ligand disclaims any intent or obligation to update any forward-looking statements beyond the date of this release. Targretin(R) is registered trademark of Ligand Pharmaceuticals Incorporated. ONTAK(R) is a registered trademark of Seragen, Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Ligand. Full prescribing information for Ligand's products may be obtained by calling Ligand Professional Services (job) professional services - A department of a supplier providing consultancy and programming manpower for the supplier's products. at 800-964-5836, or, in Europe, Ligand Pharmaceuticals International, Inc., at +44-1732-521-945. Ligand Pharmaceuticals' releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion